Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


NHS drugs bill could hit £20bn by 2021, deputy chief pharmaceutical officer warns

Delegates at the National Institute for Health and Care Excellence annual conference were told that the costs of drugs in secondary care are continuing to grow, while up to half of patients don’t take their medicines as intended.

The actual cost of the NHS’s medicine bill is contested but it continues to rise, Bruce Warner, deputy chief pharmaceutical officer at NHS England, told delegates at the National Institute for Health and Care Excellence (NICE) annual conference.

Warner told a session at the conference, held on 26 June 2018 in Manchester, that the NHS drugs bill was expected to hit £20bn by 2020/2021, adding that while the costs of drugs in primary care have largely plateaued, those in secondary care are continuing to grow.


Source: Emma Page / The Pharmaceutical Journal

Bruce Warner told a session at the National Institute for Health and Care Excellence’s annual conference that the NHS drugs bill was expected to hit £20bn by 2020/2021

The NHS drugs bill was estimated at £17.4bn in 2016/2017, an increase of around 5% a year from £13bn in 2010/2011. 

Warner said: “In addition, between 5–8% of all hospital admissions are down to adverse medicines incidents, many of which are preventable, and up to half of patients don’t take medicines as intended. The secretary of state [for health and social care] is keen that we meet this challenge of reducing harm by medicines.”

Paul Chrisp, director of the medicines and technologies programme at NICE, told the conference that better data were needed to find out which medicines offer poor value. He said the uptake of new medicines in the UK continued to be slow and variable, and that four years after approval, the NHS uptake of new medicines was only at 80% of that of 15 major European countries.

Chrisp added that there was insufficient data regarding why medicines are not taken up in greater numbers in the NHS.

“There is a lack of efficacy, or the system may not be ready, or there may not be the financial headroom available to support the system to address issues around uptake,” he said.

Paul Catchpole, director of value and access at the Association of the British Pharmaceutical Industry, also addressed the conference, saying that sufficient data could be lacking to track where value is added by the use of medicines.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205080

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Bruce Warner, deputy chief pharmaceutical officer

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.